HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1% Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Hydrocortisone Acetate 1% And Pramoxine Hydrochloride 1%, and when can generic versions of Hydrocortisone Acetate 1% And Pramoxine Hydrochloride 1% launch?
Hydrocortisone Acetate 1% And Pramoxine Hydrochloride 1% is a drug marketed by Genus and is included in one NDA.
The generic ingredient in HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1% is hydrocortisone acetate; pramoxine hydrochloride. There are sixty-seven drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the hydrocortisone acetate; pramoxine hydrochloride profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%?
- What are the global sales for HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%?
- What is Average Wholesale Price for HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%?
Summary for HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| DailyMed Link: | HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1% at DailyMed |
US Patents and Regulatory Information for HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Genus | HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1% | hydrocortisone acetate; pramoxine hydrochloride | AEROSOL, METERED;TOPICAL | 089440-001 | May 17, 1988 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
